Doris Berland, MD
Internal Medicine · Plainview, NYNPI 1558367409
Payments from drug & device makers
Across 188 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$624
- AbbVie$441
- Novartis$402
- GSK$300
- Pfizer$208
- AstraZeneca$181
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,739100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $624 |
| AbbVie | 21 | $441 |
| Novartis | 22 | $402 |
| GSK | 15 | $300 |
| Pfizer | 12 | $208 |
| AstraZeneca | 11 | $181 |
| Boehringer Ingelheim | 7 | $179 |
| Exact Sciences | 7 | $157 |
| Amgen | 5 | $130 |
| Johnson & Johnson | 6 | $111 |
| Eisai Inc. | 3 | $85 |
| Sumitomo Pharma America, Inc. | 3 | $73 |
| Lilly USA, LLC | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $58 |
| Upsher-smith Laboratories LLC | 3 | $57 |
| Astellas Pharma US Inc | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Medtronic | 2 | $42 |
| Evofem Biosciences, Inc. | 2 | $38 |
| Althera Pharmaceuticals LLC | 2 | $36 |
| GRT US Holding, Inc. | 1 | $36 |
| Philips North America LLC | 2 | $31 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $24 |
| Abbott | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Corcept Therapeutics | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Heartflow, Inc. | 1 | $16 |
| Vistapharm, Inc. | 1 | $15 |
| Merck | 1 | $14 |
How this compares
$3,739 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 91 | $101,727 |
| EliquisApixaban | 38 | $43,033 |
| XareltoRivaroxaban | 37 | $38,967 |
| JardianceEmpagliflozin | 19 | $31,262 |
| OzempicSemaglutide | 33 | $29,475 |
| WegovySemaglutide | 22 | $28,923 |
| Diclofenac Sodium | 23 | $25,645 |
| FarxigaDapagliflozin Propanediol | 17 | $22,063 |
| SynthroidLevothyroxine Sodium | 168 | $15,771 |
| Repatha SureclickEvolocumab | 22 | $11,915 |
| Rosuvastatin Calcium | 410 | $5,075 |
| Levothyroxine Sodium | 268 | $4,393 |
| Escitalopram Oxalate | 188 | $3,220 |
| Atorvastatin Calcium | 320 | $3,065 |
| Metoprolol Succinate | 184 | $2,904 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $67 | $101,72791 claims |
| Novo NordiskOzempic, Wegovy | $624 | $58,39855 claims |
| PfizerEliquis | $208 | $43,03338 claims |
| Johnson & JohnsonXarelto | $111 | $38,96737 claims |
| Boehringer IngelheimJardiance | $179 | $31,26219 claims |
| AstraZenecaFarxiga | $181 | $22,06317 claims |
| AbbVieSynthroid | $441 | $15,771168 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $4,393268 claims |
| Almatica Pharma LLCSertraline Hcl | $21 | $1,209129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Plainview
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.